Literature DB >> 16405537

The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.

George N Ioannou1, Edward J Boyko, Sum P Lee.   

Abstract

OBJECTIVES: The presence of elevated serum aminotransferase activity is a sign of possible underlying liver disease. We aimed to describe the prevalence and associations of elevated serum aminotransferase activity in a recent, nationally representative U.S. survey.
METHODS: We described the prevalence and predictors of elevated alanine aminotransferase (ALT >43 IU/L) or elevated aspartate aminotransferase (AST >40 IU/L) activity among 6,823 participants of the National Health and Nutrition Examination Survey (NHANES) conducted between 1999 and 2002. We compared our findings to the results already published based on the NHANES conducted between 1988 and 1994.
RESULTS: In NHANES 1999-2002, the prevalences of elevated ALT, AST, or either ALT or AST were 8.9%, 4.9%, and 9.8%, respectively, in the entire population and 7.3%, 3.6%, and 8.1%, respectively, after excluding participants who tested positive for hepatitis C virus (HCV) antibody or reported excessive alcohol consumption. Strong predictors of elevated ALT activity included increasing waist circumference and body mass index, alcohol consumption, male sex, Mexican American ethnicity, decreasing age, and presence of HCV antibody. In NHANES 1988-1994, which employed a different assay methodology, the prevalences of elevated aminotransferases were approximately half of the prevalences we describe in NHANES 1999-2002, but the predictors of elevated ALT activity were similar.
CONCLUSIONS: The current prevalence of elevated ALT activity in the United States (8.9%) is more than double that of previously available estimates. This prevalence is very high (7.3%) even among persons without viral hepatitis C or excessive alcohol consumption and is strongly associated with risk factors for nonalcoholic fatty liver disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405537     DOI: 10.1111/j.1572-0241.2005.00341.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  102 in total

Review 1.  Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?

Authors:  John Heineman; Sara Bubenik; Stephen McClave; Robert Martindale
Journal:  Curr Gastroenterol Rep       Date:  2012-08

2.  Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.

Authors:  N Husain; P Blais; J Kramer; M Kowalkowski; P Richardson; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2014-08-26       Impact factor: 8.171

3.  Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men.

Authors:  Raquel Villegas; Yong-Bing Xiang; Tom Elasy; Qiuyin Cai; Wanghong Xu; Honglan Li; Sergio Fazio; Macrae F Linton; David Raiford; Wei Zheng; Xiao Ou Shu
Journal:  Metab Syndr Relat Disord       Date:  2011-04-15       Impact factor: 1.894

Review 4.  Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

Authors:  Norberto-C Chavez-Tapia; Tonatiuh Barrientos-Gutierrez; Felix-I Tellez-Avila; Francisco Sanchez-Avila; Maria-Antonieta Montano-Reyes; Misael Uribe
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

5.  Association of the frequency of peripheral natural killer T cells with nonalcoholic fatty liver disease.

Authors:  Cheng-Fu Xu; Chao-Hui Yu; You-Ming Li; Lei Xu; Juan Du; Zhe Shen
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

6.  Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort.

Authors:  Mazen Noureddin; Shira Zelber-Sagi; Lynne R Wilkens; Jacqueline Porcel; Carol J Boushey; Loïc Le Marchand; Hugo R Rosen; Veronica Wendy Setiawan
Journal:  Hepatology       Date:  2020-02-14       Impact factor: 17.425

7.  The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease.

Authors:  Yuichiro Eguchi; Toshihiko Mizuta; Yoshio Sumida; Eriko Ishibashi; Yoichiro Kitajima; Hiroshi Isoda; Hiroko Horie; Takaya Tashiro; Eri Iwamoto; Hirokazu Takahashi; Takuya Kuwashiro; Shu Soejima; Yasunori Kawaguchi; Yasutomo Oda; Sei Emura; Ryuichi Iwakiri; Iwata Ozaki; Takahisa Eguchi; Naofumi Ono; Keizo Anzai; Kazuma Fujimoto; Shunzo Koizumi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

8.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.

Authors:  Zhen-Ya Lu; Zhou Shao; Ya-Li Li; Muhuyati Wulasihan; Xin-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

9.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

Review 10.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.